AR023345A1 - Compuestos moduladores de ccr5, composiciones, uso, metodo de evaluacion de un supuesto mutante del retrovirus vih, virus mutante, agente de diagnostico y procedimiento para descubrir la presencia y/o confirmar la actividad de un modulador de quimiocinas - Google Patents

Compuestos moduladores de ccr5, composiciones, uso, metodo de evaluacion de un supuesto mutante del retrovirus vih, virus mutante, agente de diagnostico y procedimiento para descubrir la presencia y/o confirmar la actividad de un modulador de quimiocinas

Info

Publication number
AR023345A1
AR023345A1 ARP990106427A ARP990106427A AR023345A1 AR 023345 A1 AR023345 A1 AR 023345A1 AR P990106427 A ARP990106427 A AR P990106427A AR P990106427 A ARP990106427 A AR P990106427A AR 023345 A1 AR023345 A1 AR 023345A1
Authority
AR
Argentina
Prior art keywords
mutant
ccr5
compositions
activity
diagnostic agent
Prior art date
Application number
ARP990106427A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9828420.1A external-priority patent/GB9828420D0/en
Priority claimed from GBGB9922009.7A external-priority patent/GB9922009D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR023345A1 publication Critical patent/AR023345A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Compuestos moduladores CCR5 de formula: [Region alfa]-[Region Beta]-[Region gamma]-[Region delta] o una sal farmacéuticamente aceptable del mismo, dondelas regiones, alfa, Beta, gamma y delta son como se describe en la memoria descriptiva. Se describen también composiciones, uso de estos moduladores, método deevaluacion de un supuesto mutante del retrovirus VIH, virus mutante, agente de diagnostico y procedimiento para descubrir y/o confirmar la actividad de unmodulador de quimiocinas.
ARP990106427A 1998-12-23 1999-12-15 Compuestos moduladores de ccr5, composiciones, uso, metodo de evaluacion de un supuesto mutante del retrovirus vih, virus mutante, agente de diagnostico y procedimiento para descubrir la presencia y/o confirmar la actividad de un modulador de quimiocinas AR023345A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9828420.1A GB9828420D0 (en) 1998-12-23 1998-12-23 CCR5 antagonists useful as anti-hiv agents
GBGB9922009.7A GB9922009D0 (en) 1999-09-18 1999-09-18 CCR5 Modulators

Publications (1)

Publication Number Publication Date
AR023345A1 true AR023345A1 (es) 2002-09-04

Family

ID=26314900

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990106427A AR023345A1 (es) 1998-12-23 1999-12-15 Compuestos moduladores de ccr5, composiciones, uso, metodo de evaluacion de un supuesto mutante del retrovirus vih, virus mutante, agente de diagnostico y procedimiento para descubrir la presencia y/o confirmar la actividad de un modulador de quimiocinas
ARP990106792A AR023363A1 (es) 1998-12-23 1999-12-28 Compuestos derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina, composicion y uso de los mismos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP990106792A AR023363A1 (es) 1998-12-23 1999-12-28 Compuestos derivados de 3,3-biarilpiperidina y 2,2-biarilmorfolina, composicion y uso de los mismos

Country Status (37)

Country Link
US (1) US7217714B1 (es)
EP (1) EP1140920A1 (es)
JP (2) JP3522691B2 (es)
KR (1) KR20010099931A (es)
CN (1) CN1150192C (es)
AP (1) AP2001002187A0 (es)
AR (2) AR023345A1 (es)
AU (1) AU769449B2 (es)
BG (1) BG105709A (es)
BR (1) BR9916585A (es)
CA (1) CA2350573C (es)
CR (1) CR6393A (es)
CZ (1) CZ20012297A3 (es)
DZ (1) DZ2978A1 (es)
EA (1) EA200100588A1 (es)
EE (1) EE200100344A (es)
GE (1) GEP20043161B (es)
HK (1) HK1039942B (es)
HN (1) HN1999000221A (es)
HR (1) HRP20010478A2 (es)
HU (1) HUP0104910A3 (es)
ID (1) ID29031A (es)
IL (1) IL143510A0 (es)
IS (1) IS5941A (es)
MA (1) MA26715A1 (es)
NO (1) NO20013149L (es)
NZ (1) NZ511796A (es)
OA (1) OA11732A (es)
PA (1) PA8488101A1 (es)
PE (1) PE20001371A1 (es)
PL (1) PL349091A1 (es)
SK (1) SK8762001A3 (es)
TN (1) TNSN99253A1 (es)
TR (2) TR200101867T2 (es)
UY (1) UY25869A1 (es)
WO (1) WO2000039125A1 (es)
YU (1) YU40701A (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399619B1 (en) 1999-04-06 2002-06-04 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1118858A3 (en) * 2000-01-12 2003-07-09 Pfizer Limited Assay method
ES2215129T3 (es) * 2000-05-26 2004-10-01 Pfizer Inc. Derivados de triazolil tropano como modulares de ccr5.
US6511994B2 (en) 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity
US6531484B2 (en) 2000-10-11 2003-03-11 Merck & Co., Inc. Pyrrolidine modulators of CCR5 chemokine receptor activity
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
US7202259B2 (en) 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
ATE555087T1 (de) 2002-11-27 2012-05-15 Incyte Corp 3-aminopyrrolidinderivate als modulatoren von chemokinrezeptoren
AU2003288994A1 (en) * 2002-12-10 2004-06-30 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
WO2004055010A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclopropyl compounds as ccr5 antagonists
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co NITROGENIC HETEROCYCLIC DERIVATIVES AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
EP2364982A1 (en) 2003-04-18 2011-09-14 ONO Pharmaceutical Co., Ltd. Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof
CA2579609A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spirohydantoin compounds and methods for the modulation of chemokine receptor activity
EP1680114A4 (en) * 2003-10-28 2008-09-24 Amgen Inc TRIAZOL COMPOUNDS AND RELEVANT PROCEDURES
CA2552087C (en) 2004-01-30 2011-01-25 Euro-Celtique S.A. Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
TW200610761A (en) * 2004-04-23 2006-04-01 Astrazeneca Ab Chemical compounds
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
WO2005121145A2 (en) 2004-06-09 2005-12-22 F. Hoffmann-La Roche Ag Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
US7858800B2 (en) 2004-06-30 2010-12-28 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
TWI400232B (zh) 2004-09-13 2013-07-01 Ono Pharmaceutical Co 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
EP1942890A4 (en) * 2005-06-15 2009-08-26 Genzyme Corp CHEMOKINE RECEPTOR BINDING COMPOUNDS
WO2006136917A1 (en) * 2005-06-22 2006-12-28 Pfizer Limited Triazolylpiperidine derivatives and use thereof in therapy
HUP0500920A2 (en) * 2005-10-05 2007-07-30 Richter Gedeon Nyrt Oxadiazole derivatives, process for their preparation and their use
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
JP5251127B2 (ja) 2005-10-28 2013-07-31 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
EP1961744B1 (en) 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
JP2009518384A (ja) * 2005-12-08 2009-05-07 ファイザー・リミテッド 化合物
EP1995246A4 (en) 2006-03-10 2010-11-17 Ono Pharmaceutical Co NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE
WO2007132846A1 (ja) 2006-05-16 2007-11-22 Ono Pharmaceutical Co., Ltd. 保護されていてもよい酸性基を含有する化合物およびその用途
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
BRPI0720436A2 (pt) 2006-12-13 2014-01-07 Hoffmann La Roche Inibidores de transcriptase reversa de não-nucleosídeo
WO2009010480A1 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. 1-{2-[(diphenyl)amino]-ethyl}-piperidine-4-carboxylic acid benzylamide derivatives and related compounds as ccr5 agonists for the treatment of immune and inflammatory diseases
EP2433936A1 (en) 2007-08-31 2012-03-28 Purdue Pharma LP Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
EA201200855A1 (ru) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. Модуляторы crth2
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009137A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103420998A (zh) * 2012-05-16 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种新型噁二唑衍生物的合成方法
CN104744451A (zh) * 2013-12-30 2015-07-01 中国科学院上海药物研究所 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
CN110628021B (zh) * 2019-09-23 2022-03-18 北京理工大学 一种侧链型磺化聚喹喔啉及其质子交换膜
CN110759902B (zh) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
CN113999103A (zh) * 2021-11-26 2022-02-01 八叶草健康产业研究院(厦门)有限公司 一种α-羟基-环丁烷甲酸的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9100505D0 (en) * 1991-01-10 1991-02-20 Shell Int Research Piperidine derivatives
GB9125900D0 (en) 1991-12-05 1992-02-05 Wyeth John & Brother Ltd Piperazine derivatives
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
GB9502644D0 (en) * 1995-02-10 1995-03-29 Zeneca Ltd Heterocyclic derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
AU1208397A (en) * 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998002151A2 (en) * 1996-07-12 1998-01-22 Leukosite, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU6133098A (en) 1997-01-21 1998-08-07 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
JP2001526178A (ja) 1997-08-28 2001-12-18 メルク エンド カムパニー インコーポレーテッド ピロリジン系およびピペリジン系ケモカイン受容体活性調節剤
AR013669A1 (es) * 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
EP1047675A1 (en) * 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
PE20001420A1 (es) * 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US6511994B2 (en) * 2000-10-11 2003-01-28 Merck & Co., Inc. Modulators of CCR5 chemokine receptor activity

Also Published As

Publication number Publication date
TR200101867T2 (tr) 2001-11-21
WO2000039125A1 (en) 2000-07-06
CR6393A (es) 2004-03-24
HUP0104910A3 (en) 2003-12-29
IL143510A0 (en) 2002-04-21
EP1140920A1 (en) 2001-10-10
AU1290400A (en) 2000-07-31
PL349091A1 (en) 2002-07-01
AP2001002187A0 (en) 2001-06-30
UY25869A1 (es) 2001-08-27
TNSN99253A1 (fr) 2005-11-10
CA2350573C (en) 2007-01-30
HRP20010478A2 (en) 2002-06-30
ID29031A (id) 2001-07-26
CN1150192C (zh) 2004-05-19
IS5941A (is) 2001-05-15
NO20013149D0 (no) 2001-06-22
SK8762001A3 (en) 2003-02-04
PE20001371A1 (es) 2000-12-14
MA26715A1 (fr) 2004-12-20
BR9916585A (pt) 2001-10-16
CA2350573A1 (en) 2000-07-06
CZ20012297A3 (cs) 2002-09-11
HK1039942B (zh) 2004-12-03
NZ511796A (en) 2003-11-28
GEP20043161B (en) 2004-01-26
KR20010099931A (ko) 2001-11-09
NO20013149L (no) 2001-08-23
AU769449B2 (en) 2004-01-29
EE200100344A (et) 2002-10-15
US7217714B1 (en) 2007-05-15
JP2004099618A (ja) 2004-04-02
TR200200938T2 (tr) 2002-05-21
HN1999000221A (es) 2001-02-02
CN1331691A (zh) 2002-01-16
BG105709A (en) 2002-02-28
OA11732A (en) 2005-05-12
EA200100588A1 (ru) 2002-02-28
HK1039942A1 (en) 2002-05-17
PA8488101A1 (es) 2002-02-21
JP2002533461A (ja) 2002-10-08
JP3522691B2 (ja) 2004-04-26
HUP0104910A2 (en) 2002-10-28
DZ2978A1 (fr) 2004-07-04
YU40701A (sh) 2004-05-12
AR023363A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
AR023345A1 (es) Compuestos moduladores de ccr5, composiciones, uso, metodo de evaluacion de un supuesto mutante del retrovirus vih, virus mutante, agente de diagnostico y procedimiento para descubrir la presencia y/o confirmar la actividad de un modulador de quimiocinas
AR024233A1 (es) Compuestos moduladores de ccr5, composiciones farmaceuticas, su uso en medicina.
BR9905977A (pt) Moduladores de ccr5
ES2044912T3 (es) Composiciones farmaceuticas dotadas de actividad secuestrante para los acidos biliares, conteniendo colestiramina como principio activo, y procedimiento para su preparacion.
HK1026691A1 (en) Substituted benzimidazoles and their use for treating retroviral infection
ES2181725T3 (es) Inhibidores de hiv proteasa.
ES2085268T3 (es) Composicion detergente enzimatica.
DK0750618T3 (da) Oxazolidinonderivater og farmaceutiske præparater indeholdende dem
ES2171670T3 (es) Sulfonamidas que contienen heterociclos oxigenados como inhibidores de la aspartil proteasa.
EE05091B1 (et) Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
ES2151600T3 (es) Derivados de n-(3-amino-2-hidroxibutil)sulfonamida utilizados como inhibidores de proteasa de vih.
ATE300541T1 (de) Pyrazolopyridinderivate
HUP0003836A2 (hu) Lazofoxifent tartalmazó gyógyszerkészítmények
CO5180558A1 (es) Derivados de n-[3-((piperidin-1-il)metil)-4-(fenil o hetero- ciclil)ciclopent-1-il]]amina utiles como moduladores de actividad del receptor de la quimioquina
ES2131015B1 (es) Nuevos derivados de 2-(3h)-oxazolona, procedimientos para su preparacion y su empleo en composiciones farmaceuticas.
ECSP993296A (es) Moduladores de ccr5
ECSP993298A (es) Moduladores de ccr5
ES2163028T3 (es) Composiciones y metodos para detectar y tratar el sindrome de la inmunodeficiencia adquirida.
MX20822A (es) Derivados de poranil cianoguanidina.
EE200200302A (et) Küllastumata 14,15-tsüklopropanoandrostaanid, nende valmistamise meetod ja neid ühendeid sisaldavadfarmatseutilised kompositsioonid
PA8448801A1 (es) Inhibidores de la proteasa del vih
ECSP003799A (es) Nuevos esteroides con actividad androgenica y su uso como anticonceptivos masculinos y para tratar la insuficiencia androgenica.

Legal Events

Date Code Title Description
FB Suspension of granting procedure